证券代码：000876 证券简称：新希望 公告编号：2025-70 债券代码：127015,127049 债券简称：希望转债，希望转 2 新希望六和股份有限公司 关于召开 2025 年第二次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 1．本次股东会为公司2025年第二次临时股东会。 2．会议的召集人为公司董事会，召开事项于2025年7月13日公司 第十届董事会第四次会议审议通过。 3．本次会议的召开合法、合规，符合有关法律、行政法规、部 门规章、规范性文件和公司《章程》的规定。 4．会议召开日期、时间 现场会议召开时间：2025年7月31日（星期四）下午14:00。 通过深圳证券交易所交易系统进行网络投票的时间为2025年7月 31日上午9:15—9:25、9:30—11:30，下午13:00—15:00。 通过互联网投票系统（http://wltp.cninfo.com.cn）投票的具体时间 为：2025年7月31日9:15-15:00。 5．会议召开方式：本次股东会采用现场表决与网络投票相结合 的方式召开。 6 ...

证券代码：000876 证券简称：新希望 公告编号：2025-67 债券代码：127015,127049 债券简称：希望转债，希望转 2 新希望六和股份有限公司 表决结果：3 票赞成，0 票反对，0 票弃权。 第十届监事会第四次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 新希望六和股份有限公司（以下简称"公司"）第十届监事会第 四次会议通知于 2025 年 7 月 12 日以电子邮件方式通知了全体监事。 第十届监事会第四次会议于 2025 年 7 月 13 日以通讯表决方式召开， 本次会议应参加表决监事 3 人，实际表决监事 3 人。本次会议的召开 符合有关法律、行政法规、部门规章、规范性文件和公司《章程》的 规定，所作决议合法有效。 二、监事会会议审议情况 本次会议由监事以传真方式会签，审议通过了如下议案： （一）审议通过了"关于延长向特定对象发行 A 股股票股东会决 议有效期的议案" 经公司 2024 年第一次临时股东大会审议，公司本次向特定对象 发行 A 股股票决议的有效期为十二个月，自发行方案经股东大会审议 通 ...

| | | 证券代码：000876 证券简称：新希望 公告编号：2025-66 债券代码：127015,127049 债券简称：希望转债，希望转 2 新希望六和股份有限公司（以下简称"公司"）第十届董事会第 四次会议通知于 2025 年 7 月 12 日以电子邮件方式通知了全体董事。 第十届董事会第四次会议于 2025 年 7 月 13 日以通讯表决方式召开。 本次会议应参加表决董事 9 人，实际表决董事 8 人，独立董事彭龙先 生因正在接受纪律审查和监察调查，缺席本次会议。本次会议的召开 符合有关法律、行政法规、部门规章、规范性文件和公司《章程》的 规定，所作决议合法有效。 二、董事会会议审议情况 本次会议由董事以传真方式会签，审议通过了如下议案： （一）审议通过了"关于免去彭龙先生独立董事职务的议案" 表决结果：8 票赞成，0 票反对，0 票弃权。 因公司独立董事彭龙先生正在接受纪律审查和监察调查，无法正 常履职，为保证公司董事会的正常运作，公司董事会决定免去彭龙先 生的独立董事职务及其在董事会各专门委员会中担任的全部职务，免 职后，彭龙先生将不再担任公司任何职务。 新希望六和股份有限公司 第十届董事会第 ...

证券代码：000876 证券简称：新希望 公告编号：2025-73 债券代码：127015,127049 债券简称：希望转债，希望转 2 新希望六和股份有限公司 2025 年半年度业绩预告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、本期业绩预计情况 1.业绩预告期间：2025 年 1 月 1 日至 2025 年 6 月 30 日 2. 预计的经营业绩： | 项 目 | 本报告期 | | | 上年同期 | | --- | --- | --- | --- | --- | | 归属于上市公司 股东的净利润 | 盈利：68,000 | 万元–78,000 | 万元 | 亏损：121,747.67 万元 | | | 比上年同期增长：155.85%–164.07% | | | | | 扣除非经常性损 益后的净利润 | 盈利：62,700 | 万元–72,700 | 万元 | 亏损：131,630.65 万元 | | | 比上年同期增长：147.63%–155.23% | | | | | 基本每股收益 | 盈利：0.14 | 元/股–0.16 | 元/股 | 亏损 ...

新希望（000876）公告，预计2025年上半年净利润为6.8亿元–7.8亿元，同比扭亏为盈，上年同期为亏损 12.17亿元。 ...

Core Viewpoint - AstraZeneca's innovative drug baxdrostat shows significant blood pressure reduction in patients with resistant hypertension, indicating a potential breakthrough in hypertension treatment [1][2] Group 1: Drug Efficacy and Research - Despite existing hypertension treatments, half of the patients do not achieve adequate blood pressure control [1] - In a late-stage trial, baxdrostat significantly lowered systolic blood pressure compared to the placebo group, achieving both primary and secondary endpoints [1] - The drug targets aldosterone, a hormone that raises blood pressure, with approximately 25% of hypertension cases linked to aldosterone level dysregulation [1] Group 2: Market Potential and Sales Forecast - AstraZeneca acquired CinCor Pharma in 2023, expanding its product line in cardiovascular and renal disease treatments with baxdrostat [1] - The company anticipates peak annual sales for baxdrostat to exceed $5 billion, with potential for use alone or in combination with Farxiga, another cardiovascular therapy [2] - Farxiga currently generates over $1 billion in annual sales, used for treating type 2 diabetes, heart failure, and chronic kidney disease [2] Group 3: Ongoing Clinical Trials - AstraZeneca is conducting a large-scale clinical study involving over 20,000 patients to test baxdrostat's efficacy across four indications, including chronic kidney disease and heart failure prevention [2] - Full trial results for baxdrostat are expected to be presented at the European Society of Cardiology (ESC) annual meeting in August [2] - China is participating in this global clinical trial [2] Group 4: Competitive Landscape - Mineralys Therapeutics is also developing a drug, lorundrostat, targeting aldosterone, with plans to submit data to the FDA by the end of the year [2]

Core Viewpoint - The article discusses the recent decline in pig prices and the overall performance of the pig farming industry, highlighting changes in supply, demand, and pricing dynamics [3][4]. Group 1: Pig Price Trends - As of July 11, the average price of external three yuan pigs in China was 14.81 yuan/kg, reflecting a week-on-week decrease of 3.52%. The average price for 15 kg piglets was 31.89 yuan/kg, showing a week-on-week increase of 1.79% [3]. - The average weight of market pigs sold this week was 129.03 kg, which is an increase of 0.39 kg compared to the previous week. The national frozen product inventory rate rose to 14.31%, up by 0.08 percentage points [3]. Group 2: June Sales Report Analysis - In June, 13 listed pig companies collectively sold 16.2681 million pigs, representing a month-on-month increase of 2.65% and a year-on-year increase of 47.55%. Major companies like Muyuan, Wens, and New Hope saw varying changes in their sales volumes [4]. - The total number of market pigs sold in June was approximately 13.5449 million, with a month-on-month increase of 3.30% and a year-on-year increase of 43.36%. The sales of piglets decreased slightly by 1.90% month-on-month but increased by 74.14% year-on-year [4]. - The average selling price of market pigs decreased due to inventory reduction, with most companies experiencing a price drop of less than 3% month-on-month and approximately 20% year-on-year [4]. Group 3: Weight and Pricing Dynamics - The average weight of market pigs sold in June was 125.06 kg, down by 0.77 kg month-on-month, indicating a trend towards reducing weight as companies adjust to market conditions [4]. - The average selling price varied among companies, with the lowest at 13.23 yuan/kg and the highest at 15.57 yuan/kg, with most companies maintaining prices between 14-15 yuan/kg [4].

Investment Rating - Industry Rating: Outperform the market (maintained rating) [12] Core Views - The report emphasizes the importance of the pig sector, noting a slowdown in the growth rate of breeding sows in June, and highlights the expectation gap in the pig market [1][2] - The pet sector is witnessing a rise in domestic brands and a positive trend in pet food exports, indicating a robust growth potential [3][4] - The poultry sector is focusing on the breeding gap for white chickens and the marginal improvement in demand for yellow chickens, with investment recommendations based on supply and demand dynamics [5][6][7] - The planting sector is prioritizing food security and the strategic importance of biological breeding, with recommendations for key seed and agricultural companies [9][10] - The feed sector is recommended for companies with increasing market share and consistent performance, while the animal health sector is advised to focus on new demands and innovative products [24][25] Summary by Sections Pig Sector - As of July 12, the average price of pigs in China is 14.91 CNY/kg, down 2.42% from the previous week, with self-breeding profits around 177 CNY per head [1][16] - The report highlights the low valuation and expectation gap in the pig sector, recommending leading companies such as Muyuan Foods and Wens Foodstuffs [2][16] Pet Sector - In June 2025, pet sales on Douyin reached 964 million CNY, a year-on-year increase of 73.97%, indicating strong growth for domestic brands [3][17] - Pet food exports from China increased by 10.89% year-on-year in the first five months of 2025, reaching 41.75 billion CNY [4][17] Poultry Sector - The report notes a 33.46% year-on-year decline in the breeding stock of grandparent chickens due to import restrictions, with a total of 529,300 sets updated in the first half of 2025 [5][19] - Investment recommendations include focusing on companies like Shengnong Development and Yisheng Livestock [6][20] Planting Sector - The report stresses the need for high yield production to ensure food security, with a focus on integrating advanced agricultural technologies [9][23] - Key recommendations include leading seed companies such as Longping High-Tech and Dabeinong [10][23] Feed and Animal Health Sectors - The feed sector is highlighted for companies like Haida Group, which is expected to benefit from market share growth and performance consistency [24][26] - The animal health sector is advised to focus on new product development and market expansion, particularly in the pet health segment [25][26]

Core Insights - The Yttrium-90 microsphere injection, 易甘泰®, has benefited over 3,000 liver cancer patients since its launch in mainland China in 2022, showcasing its significant impact in the treatment of liver tumors [1] - The product received FDA approval for a new indication for unresectable hepatocellular carcinoma (HCC) on July 7, 2025, making it the first and only selective internal radiation therapy product approved for both unresectable HCC and colorectal cancer liver metastases [1][5] - The 15 abstracts related to Yttrium-90 microspheres presented at the 15th Asia-Pacific Primary Liver Cancer Expert Alliance (APPLE) conference highlight its clinical applicability and effectiveness across different stages of HCC [4][2] Group 1: FDA Approval and Clinical Impact - The FDA's early approval was based on the promising mid-term results of the DOORwaY90 clinical trial, which reported an objective response rate of 98.5% and a local tumor control rate of 100% [4][5] - The approval aligns with real-world data from Chinese patients, indicating broad applicability of 易甘泰® in local clinical settings [4] - The product's success is expected to accelerate its commercialization in China and reshape the treatment landscape for liver cancer [1][5] Group 2: Market Context and Future Prospects - According to GLOBOCAN 2022, liver cancer is the sixth most common cancer globally, with approximately 870,000 new cases and 760,000 deaths annually [6] - In China, liver cancer accounted for about 370,000 new cases in 2022, representing 42.5% of global cases, and the mortality rate was approximately 320,000, also the highest globally [6][8] - The Chinese liver cancer drug market is projected to grow at a compound annual growth rate (CAGR) of 12.3%, reaching 45.21 billion yuan by 2030 [8][9] Group 3: Company Development and Innovation - The company has established a comprehensive nuclear medicine industry chain, covering research, production, sales, and regulatory qualifications, with 15 innovative products in the pipeline targeting various cancers [11][17] - The newly launched Chengdu Wenjiang nuclear medicine R&D and production base, with an investment exceeding 3 billion yuan, aims to enhance production capabilities and meet domestic and international demands [17][19] - The base features advanced automation and a full-process radiation monitoring system, positioning the company as a leader in the nuclear medicine sector [18][19]

Investment Rating - The report maintains a "Buy" rating for the agriculture, forestry, animal husbandry, and fishery sector [4] Core Viewpoints - Recent policy guidance has led to a rapid decline in post-slaughter weight, allowing for a rebalancing of volume and price, with positive expectations for pig prices [3] - The long-term perspective indicates that the bottom of the production capacity cycle is becoming clearer, suggesting a potential long-term profit upturn for the sector [3] - The report highlights investment opportunities in various segments, including pig farming, feed, and planting chains, as well as the pet food sector [3] Summary by Sections Pig Farming Sector - In June, 13 listed pig companies collectively slaughtered 16.2681 million pigs, a month-on-month increase of 2.65% and a year-on-year increase of 47.55% [2][13] - The average selling price of pigs decreased by approximately 3% month-on-month and about 20% year-on-year, with prices ranging from 13.23 to 15.57 yuan/kg [14][15] - The average weight of slaughtered pigs in June was 125.06 kg, down 0.77 kg from May, indicating a trend towards reducing weight [17] Market Dynamics - The national average price for live pigs was 14.81 yuan/kg as of July 11, reflecting a week-on-week decline of 3.52% [28] - The demand for pork is weakening due to high temperatures affecting consumption and rising storage costs, leading to a gradual loosening of supply-demand dynamics [28] Investment Recommendations - The report recommends focusing on leading companies such as Muyuan Foods, Wens Foodstuff, and Juxing Agriculture, as well as companies in the feed and animal health sectors like Haida Group and Ruipu Biological [3] - In the planting chain, opportunities are highlighted for companies like Suqian Agricultural Development and Beidahuang [3] Other Segments - The pet food industry is experiencing growth, with increasing recognition of domestic brands and continuous growth of leading companies [3]